

## References

- 1 Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000; **92**:1500–10.
- 2 Silverberg MJ, Lau B, Achenbach CJ et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. *Ann Intern Med* 2015; **163**:507–18.
- 3 Kreuter A, Potthoff A, Brockmeyer NH et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. *Br J Dermatol* 2010; **162**:1269–77.
- 4 Esser S, Kreuter A, Oette M et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. *J Dtsch Dermatol Ges* 2015; **13**:1302–19.
- 5 Brickman C, Palefsky JM. Cancer in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. *Curr HIV/AIDS Rep* 2015; **12**:388–96.
- 6 Fuchs W, Wieland U, Skaletz-Rorowski A et al. The male Screening Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. *J Eur Acad Dermatol Venereol* 2016; **30**:995–1001.
- 7 Richel O, Hallensleben ND, Kreuter A et al. High-resolution anoscopy: clinical features of anal intraepithelial neoplasia in HIV-positive men. *Dis Colon Rectum* 2013; **56**:1237–42.
- 8 Jay N, Berry JM, Miaskowski C et al. Colposcopic characteristics and Lugol's staining differentiate anal high-grade and low-grade squamous intraepithelial lesions during high resolution anoscopy. *Papillomavirus Res* 2015; **1**:101–8.
- 9 Siegenbeek van Heukelom ML, Richel O, de Vries HJC et al. Low- and high-risk human papillomavirus genotype infections in intra-anal warts in HIV-positive men who have sex with men. *Br J Dermatol* 2016; **175**:735–43.
- 10 Berry JM, Jay N, Cranston RD et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. *Int J Cancer* 2014; **134**:1147–55.

## Dermatoscopy in general practice

DOI: 10.1111/bjd.14609

**Linked Article:** Chappuis et al. *Br J Dermatol* 2016; **175**:744–750.

'Melanoma writes its message on the skin with its own ink and it is there for all to see. Unfortunately some see but do not comprehend.' Since Neville Davis made this statement in the *Annals of Plastic Surgery* in 1978,<sup>1</sup> the advent of dermatoscopy has facilitated earlier diagnosis of melanoma, as well as enhancing diagnostic accuracy for many dermatological conditions, both benign and malignant. Such is the level of evidence for the diagnosis of melanoma that dermatoscopy is now the standard of care in Australasia for clinicians treating pigmented skin lesions.<sup>2</sup> With skin conditions accounting for up to 14·8% of all consultations in general practice<sup>3</sup> it has been suggested that dermatoscopy is now as applicable in that discipline as is use of the stethoscope.<sup>4</sup>

In their study in this edition of the *BJD*, Chappuis et al. deliver detailed findings of the first assessment of dermatoscopy use by French general practitioners (GPs),<sup>5</sup> reporting that 8% of respondents possessed a dermatoscope and 16·9% had received training in dermatoscopy.

This low level of usage of dermatoscopy is not unique to GPs or to France. Studies on dermatoscopy use, cited in the study by Chappuis et al.,<sup>5</sup> suggest that while use appears to be high by dermatologists in Europe and Australia (94·6% in France<sup>6</sup> and 98% in Australia<sup>7</sup>), less than half of the dermatologists surveyed in a cross-sectional survey in the U.S.A. in 2010 had used a dermatoscope,<sup>8</sup> although a more recent survey suggests use may have increased to around 79%.<sup>9</sup> The only other study that attempted to quantify dermatoscopy use by GPs reported that one-third of respondents, in Australia in 2007, used dermatoscopy.<sup>10</sup>

In the twenty-first century, debate about the merits of dermatoscopy is as inappropriate as debate about the merits of using an otoscope. Cited drawbacks such as cost and time constraints are no longer tenable and any perceived lack of efficacy of dermatoscopy is likely to be related to lack of training and experience rather than to science.

It is time for a paradigm shift in attitude and practice and such changes start not at workshops for graduate doctors, no matter how appropriate these are, but in medical school. The kit of stethoscope, patella hammer, ophthalmoscope and otoscope, which adorned the twentieth-century medical student's white coat, should have the dermatoscope added to it. Instruction in the use of this relatively low-cost hand-held device should be an integral part of teaching in medical school as well as in advanced training programmes for GPs.

The study by Chappuis et al. found that GPs in France were receptive to training in dermatoscopy.<sup>5</sup> The time is ripe to respond to this, not only for GPs in France, but for medical students globally. This will bring us one step closer to the dream of the late Bernie Ackerman: that no person should die of melanoma.<sup>11</sup>

## Acknowledgments

The author wishes to acknowledge H. Peter Soyer for his thoughtful comments and advice.

## Conflicts of interest

C.R. is the Academic Director of the Master of Medicine (Skin Cancer) Program at the School of Medicine, The University of Queensland, Australia.

School of Medicine, The University of  
Queensland Australia, Brisbane, Australia  
E-mail: cliffrosendahl@bigpond.com

C. ROSENDAHL

## References

- 1 Davis N. Modern concepts of melanoma and its management. *Ann Plast Surg* 1978; **1**:628–9.

- 2 Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Evidence-based Best Practice Guidelines. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008; xxii.
- 3 Britt H, Miller GC, Charles J et al. General practice activity in Australia 2009–2010. General practice series no. 27, cat. no. GEP 27. Canberra: AIHW, 2010. Available at: <http://www.aihw.gov.au/publication-detail/?id=6442472433> (last accessed 18 March 2016).
- 4 Rosendahl C, Cameron A, McColl I, Wilkinson D. Dermoscopy in routine practice – ‘Chaos and Clues’. *Aust Fam Physician* 2012; **41**:482–7.
- 5 Chappuis P, Duru G, Marchal O et al. Dermoscopy, a useful tool for general practitioners in melanoma screening: a nationwide survey. *Br J Dermatol* 2016; **175**:744–50.
- 6 Moulin C, Poulalhon N, Duru G et al. Dermoscopy use by French private practice dermatologists: a nationwide survey. *Br J Dermatol* 2013; **168**:74–9.
- 7 Venugopal SS, Soyer HP, Menzies SW. Results of a nationwide dermoscopy survey investigating the prevalence, advantages and disadvantages of dermoscopy use among Australian dermatologists. *Australas J Dermatol* 2011; **52**:14–18.
- 8 Engasser HC, Warshaw EM. Dermoscopy use by US dermatologists: a cross-sectional survey. *J Am Acad Dermatol* 2010; **63**:412–19.
- 9 Winkelmann RR, Rigel DS. Management of dysplastic nevi: a 14-year follow-up survey assessing practice trends among US dermatologists. *J Am Acad Dermatol* 2015; **73**:1056–9.
- 10 Chamberlain AJ, Kelly JW. Use of dermoscopy in Australia. *Med J Aust* 2007; **187**:252–3.
- 11 Ackerman AB. No one should die of malignant melanoma. *J Am Acad Dermatol* 1985; **12**(1 Pt 1):115–16.

## Dermoscopy for basal cell carcinoma subtype prediction

DOI: 10.1111/bjd.14657

**Linked Article:** Ahnlide et al. *Br J Dermatol* 2016; **175**:751–761.

In the current issue of the *BJD*, Ahnlide et al. assessed the value of dermoscopy in predicting the histopathological subtype of basal cell carcinoma (BCC).<sup>1</sup> The value of dermoscopy for the diagnosis of BCC has been documented extensively in the literature.<sup>2,3</sup> Both pigmented and nonpigmented BCC is known to display characteristic dermoscopic criteria that significantly enhance its clinical recognition.<sup>4,5</sup> The diagnostic accuracy of dermoscopy for BCC has been reported to range between 95% and 99%, depending on BCC type and on the set of diseases included in the control group.<sup>2,3,6</sup>

In addition to its unquestionable value for BCC diagnosis, dermoscopy has recently been shown to be beneficial also for the management of the tumour, by providing information relevant for the selection of the optimal treatment, as well as the evaluation of the treatment outcome.<sup>7–9</sup> The study by Ahnlide et al. confirms the previously suggested usefulness of dermoscopy for subtype prediction and provides novel information on the most potent dermoscopic predictors of superficial BCC (sBCC) in a fair-skinned population. The investigators performed a prospective study in two

periods, one with optional and one with obligatory use of dermoscopy, after a short educational intervention. The analysis highlighted that BCC subtype prediction was significantly more accurate when naked-eye examination was coupled with dermoscopy. A flat surface and the dermoscopic presence of multiple small erosions represented the most robust criteria suggestive of sBCC.<sup>1</sup>

The introduction of effective nonsurgical treatment modalities in skin oncology questioned the traditional notion that the management of skin cancer should always be surgical. Undoubtedly, surgery remains the therapeutic mainstay for skin cancer, being considered to be the only reasonable choice for melanoma and the treatment of choice for the majority of nonmelanoma skin cancers.<sup>5</sup> However, nonsurgical modalities continuously gain appreciation especially for the treatment of in situ epithelial cancer, including sBCC and in situ squamous cell carcinoma.<sup>5</sup> For a few years now, guidelines on BCC management have suggested imiquimod and photodynamic therapy (PDT) as first options for the management of low-risk sBCC, with surgery remaining the first-line treatment for high-risk sBCC and, of course, for all invasive subtypes.<sup>10</sup> This suggestion is based on the documented very high response rates of sBCC to imiquimod and PDT, which have been reported as high as 99%. In contrast, surgery of sBCC is known to be associated with a high recurrence rate, because of the biological tendency of the tumour to grow peripherally beyond clinically visible margins. In nodular BCC, instead, the efficacy of nonsurgical modalities has been reported much lower, while surgery usually results in complete tumour eradication.<sup>10</sup>

Effectively, having an accurate estimation of BCC subtype would allow clinicians to individualize BCC management, choosing the most appropriate treatment for each patient, and therefore reducing treatment failures.

In the study by Ahnlide et al., the addition of dermoscopy to the naked-eye clinical examination improved all measures of diagnostic accuracy for sBCC.<sup>1</sup> From a clinical point of view, the most relevant measure would be the specificity for sBCC diagnosis, as it reflects the possibility of misdiagnosing and undertreating a nonsuperficial tumour as an sBCC. The study showed a significant increase of the specificity of sBCC diagnosis when dermoscopy was added. The latter finding is in line with a previous study introducing the value of dermoscopy in subtype prediction, while other studies showed that it may also provide other information that might influence the treatment selection.<sup>7,11</sup> Added to all these data, the study by Ahnlide et al. elevates the level of evidence supporting that the dermatoscope is a useful and reliable clinical tool for the diagnosis and management of BCC.

## Funding sources

No external funding.

## Conflicts of interest

None to declare.